2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le vendredi 8 novembre 2019
Doi : 10.1016/j.jaad.2019.05.102
accepted : 30 May 2019
Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis

Harrison H. Lee, BS a, Kevin R. Patel, MD a, Supriya Rastogi, MD a, Vivek Singam, MD a, Paras P. Vakharia, MD, PharmD a, Rishi Chopra, MD, MS a, Jonathan I. Silverberg, MD, PhD, MPH a, b, c, d,
a Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 
b Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 
c Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois 
d Northwestern Medicine Multidisciplinary Eczema Center, Chicago, Illinois 

Correspondence to: Jonathan I. Silverberg, MD, PhD, MPH, 676 N St. Clair St, Ste 1600, Chicago, IL 60611.676 N St. Clair StSte 1600ChicagoIL60611

Atopic dermatitis (AD) has a variable disease course and intermittent triggers, and responses to topical therapy vary, potentially affecting the magnitude of the placebo response in AD trials.


To determine the predictors of increased placebo response in randomized controlled trials of AD.


We performed a systematic review and meta-analysis of randomized controlled trials for systemic therapy in AD published during 2007-2018. We searched the Cochrane Library, Medline, Embase, Global Resource for EczemA Trials (GREAT), Literature of the Latin American and Caribbean Health Sciences (LILACS), and Scopus. Two authors performed study selection and data extraction. Multivariable mixed models were constructed for Cohen D of Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), numeric rating scale (NRS)–itch and visual analog scale (VAS)–itch, and Dermatology Life Quality Index (DLQI).


Overall, 64 trials were included. Use of concomitant topical therapy prescriptions, study duration ≥3 months, and fewer treatment arms were associated with an increased placebo response for EASI, NRS- and VAS-itch, and DLQI. For EASI, the placebo response was increased in studies with a higher proportion of male patients, mild-moderate mean baseline EASI scores, and no blinding. For NRS-itch, and VRS-itch, higher placebo responses were associated with higher proportions of male patients and moderate-severe mean itch scores at baseline.


Placebo responses can be reduced in clinical trials of systemic therapy in AD by incorporating double- and triple-blinding, balancing the sex distribution of patients, disallowing concomitant use of prescription topical therapy, and having shorter study durations.

The full text of this article is available in PDF format.

Key words : atopic dermatitis, eczema, meta-analysis, placebo responses, randomized controlled trial, systematic review, systemic therapy

Abbreviations used : AD, CI, DLQI, EASI, NRS, RCT, SCORAD, SD, TCS, VAS

 Funding sources: Supported by the Dermatology Foundation.
 Conflicts of interest: None disclosed.
 Reprints not available from the authors.

© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline